
From Cancer Drugs to Kilowatts: LIXTE’s Radical AI Pivot
In a total corporate metamorphosis, clinical-stage biotech firm LIXTE Biotechnology Holdings is abandoning oncology to become a power-infrastructure provider. The NASDAQ-listed company intends to acquire NOMAD Transportable Power Systems, aiming to solve the acute electrical capacity shortages currently throttling the North American artificial intelligence boom.


























